Haemonetics (HAE) EBITDA (2009 - 2026)

Haemonetics has reported EBITDA for 18 years, with the latest figure at -$23.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 132.28% year-over-year to -$23.0 million; the trailing twelve-month figure through Mar 2026 stood at $156.7 million (down 2.75% YoY), and the FY2026 full-year result was $156.7 million, down 29.34% from the prior year.
• EBITDA for Q1 2026 stood at -$23.0 million, down from $67.4 million in the prior quarter.
• The five-year high for EBITDA was $71.3 million in Q1 2025, with the low at -$23.0 million in Q1 2026.
• Average EBITDA over 5 years is $33.6 million, with a median of $33.3 million recorded in 2023.
• Year-over-year, EBITDA jumped 427.28% in 2022 and slumped 132.28% in 2026.
• Tracing HAE's EBITDA over 5 years: stood at $37.4 million in 2022, then gained by 5.79% to $39.6 million in 2023, then plunged by 58.15% to $16.6 million in 2024, then jumped by 307.05% to $67.4 million in 2025, then tumbled by 134.16% to -$23.0 million in 2026.
• The last three EBITDA figures came in at -$23.0 million (Q1 2026), $67.4 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.

Peer Comparison